[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiation-exposure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiation-exposure":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,47,73,99,126,155,189,215,243,265],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100414564","zero-fluoroscopy-voltage-guided-vs-linear-cti-ablation-100414564",false,"NCT04678258","Zero Fluoroscopy Voltage Guided vs. Linear CTI Ablation","A Zero Fluoroscopy Maximum Voltage Guided Stepwise Approach Using IntellaMiFi Technology Compared to Linear Ablation of the Cavotricuspid Isthmus for Typical Atrial Flutter: the ZERO MAGIC Trial","ZERO MAGIC","Inclusion Criteria:\n\n* Typical (CTI dependent) atrial flutter documented in a standard 12 lead surface ECG\n* Given class I indication for curative CTI ablation according to the current guidelines\n* Over 18 years old\n* Given informed consent\n\nExclusion Criteria:\n\n* Any contraindication for CTI ablation\n* Previous CTI ablation\n* BCB as procedural endpoint not assessable\n* CTI ablation conducted in association with further ablation procedures\n* Patients with CIED (e.g. pacemaker, ICD)\n* Tricuspid valve replacement\n* Right atrial thrombus\n* Pregnant or breastfeeding women\n* Abuse of drugs or alcohol\n* Age \\\u003C 18 years\n* Incompliance to the treatment, e.g. necessary anticoagulation\n* Expected survival less than one year\n* Inability to understand the nature and rationale of the study\n* Inability to take part in the follow up","ALL","18 Years",{"count":20,"type":21},106,"ESTIMATED","INTERVENTIONAL",[24],"NA","Catheter ablation of the cavo-tricuspid isthmus (CTI) is the curative first-line therapy for typical atrial flutter. Currently, two approaches are used in clinical practice. In contrast to the conventional linear ablation approach, the Maximum voltage-guided (MVG) strategy aims to limit ablation to high voltage areas (HVAs) representing the detectable correlate of relevant conducting bundles. Data from registries show that the MVG technique is sufficient to reach comparable clinical outcome with significantly shorter ablation duration when compared to the conventional linear strategy.\n\nDespite growing evidence, however, data from properly powered prospective randomized trials are lacking and the linear approach still remains standard. In addition, data on radiation exposure are controversial.\n\nAs a substrate-based approach, the MVG strategy requires detailed mapping and signal analysis for identification of the individual architecture and exactly targeted energy application. However, the spatial mapping resolution of large tip catheters is limited. The use of the MicroFidelity catheter technology (IntellaMiFi) with high resolution mini-electrodes at the 8 mm catheter tip can be expected to further improve the feasibility of a voltage-guided approach. In addition, the MVG approach theoretically may encompass an increased risk for clinically inapparent reconduction. A prospective study with predefined invasive re-evaluation of persistent CTI block is needed to further evaluate this issue.\n\nObjective of this prospective randomized study is evaluate the performance of the micro-sensor technology for zero-fluoroscopy voltage-guided ablation of typical atrial flutter (AFL) compared with a population undergoing conventional linear ablation including a predefined invasive re-evaluation of persistent CTI block in addition to clinical follow-up.\n\nThe study has been approved by the responsible ethics committee.",[27,28,29],"Catheter Ablation","Atrial Flutter Typical","Radiation Exposure",[31,32,33],"atrial flutter typical","catheter ablation","electroanatomic mapping","RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-15","ACTUAL",{"date":40,"type":38},"2020-11-30",{"date":42,"type":21},"2027-08-31",{"name":44,"class":45},"Klinikum-Fuerth","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100639793","comparison-of-operator-radiation-exposure-during-percutaneous-coronary-intervention-between-left-distal-and-right-conventional-radial-access-100639793","NCT07579169","Comparison of Operator Radiation Exposure During Percutaneous Coronary Intervention Between Left Distal and Right Conventional Radial Access","Comparison of Operator Radiation Exposure During Percutaneous Coronary Intervention Between Left Distal and Right Conventional Radial Access: A Multicenter, Randomized Trial","DOSE-PCI","Inclusion Criteria:\n\n1. Patients aged 19 years or older\n2. Patients scheduled for PCI\n\nExclusion Criteria:\n\n1. Non-palpable left distal radial artery pulse\n2. Non-palpable right radial artery pulse\n3. Presence of arteriovenous fistula\n4. Need for femoral access as determined by the investigator\n5. Refusal to provide informed consent\n6. Pregnant or breastfeeding women","20 Years",{"count":57,"type":21},748,[24],"This study aims to compare the operator's radiation exposure between left distal radial access (LDRA) and right transradial access (RTRA) in patients undergoing percutaneous coronary intervention (PCI).",[29],[53],"NOT_YET_RECRUITING","2026-05-21",{"date":65,"type":38},"2026-05-27",{"date":67,"type":21},"2026-06-01",{"date":69,"type":21},"2029-04-21",{"name":71,"class":45},"Yonsei University",4,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":46},"100638365","randomized-trial-of-next-generation-fluoroscopy-system-vs-conventional-fluoroscopy-system-in-endoscopy-100638365","NCT07594132","Randomized Trial of Next Generation Fluoroscopy System vs. Conventional Fluoroscopy System in Endoscopy","Randomized Trial Comparing Next Generation Fluoroscopy System With Conventional Fluoroscopy System in Fluoroscopy-guided Endoscopic Procedures","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients undergoing fluoroscopy-guided endoscopic procedure\n* Physicians and anesthesia staff participating in endoscopic procedures\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnancy",{"count":81,"type":21},108,[24],"Fluoroscopy is an integral part of both basic and advanced gastrointestinal endoscopy procedures. Given the risks of radiation exposure and inherent limitations of preventive measures, there is a need for additional effective protective methods.\n\nIn this randomized trial, we will be comparing radiation exposure between a next generation fluoroscopy system and conventional fluoroscopy system during fluoroscopy-guided endoscopic procedures.",[29],[86,87,88,89],"Endoscopic ultrasound","Endoscopic retrograde cholangiopancreatography","Endoscopy","Fluoroscopy","2026-05-11",{"date":92,"type":38},"2026-05-18",{"date":94,"type":21},"2026-05",{"date":96,"type":21},"2028-04",{"name":98,"class":45},"Orlando Health, Inc.",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":46},"100402988","fluoroscopy-radiation-reduction-during-sacral-neuromodulation-lead-placement-100402988","NCT04527445","Fluoroscopy Radiation Reduction During Sacral Neuromodulation Lead Placement","Reduction in Fluoroscopy Radiation Exposure During Lead Implantation for Sacral Neuromodulation: A Randomized Prospective Study","Inclusion Criteria:\n\n* Patients undergoing lead implantation for sacral neuromodulation that have overactive bladder as defined by urinary urgency, frequency, nocturia with or without urgency incontinence.\n\nExclusion Criteria:\n\n* neurogenic bladder, BMI \\>40, or peripheral neuropathy.","89 Years",{"count":108,"type":21},44,[24],"Fluoroscopy is performed when placing a lead during a sacral neuromodulation procedure. During lead placement, subjects will receive either conventional or experimental fluoroscopic settings. The radiation exposure will be compared between the two groups.",[29,112,113,114],"Overactive Bladder","Urge Incontinence","Urgency-frequency Syndrome",[116,89],"Sacral Neuromodulation","2026-03-04",{"date":119,"type":38},"2026-03-06",{"date":121,"type":21},"2026-06",{"date":123,"type":21},"2027-06",{"name":125,"class":45},"Loma Linda University",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":46},"100583381","the-radiation-protection-for-dose-reduction-in-the-cardiac-catheter-lab-study-the-reduce-trial-100583381","NCT06875583","The Radiation ProtEction for Dose RedUction in the Cardiac CathEter Lab Study: The REDUCE Trial","REDUCE","Inclusion Criteria:\n\n* All procedures involving adult patients (\\>18 year of age)\n* Male or female patients\n* Planned to undergo either an elective or urgent coronary intervention procedure involving ionising radiation in the cardiac catheter lab, via the right and or left radial arteries.\n\nExclusion Criteria:\n\n* Procedures involving patients less than 18 years of age\n* Patients unable to give valid consent\n* Pregnancy\n* Femoral approach procedure",{"count":134,"type":21},100,[24],"Doctors and nurses who perform heart procedures using X-ray guidance are exposed to radiation, which can be harmful over time. This exposure increases the risk of certain health problems, including cancers, eye damage (cataracts), and DNA damage. Although protective lead clothing is used to reduce exposure, it is heavy, uncomfortable, and can cause muscle and joint problems for those who wear it daily.\n\nA new radiation protection device, called RAMPART, may help reduce radiation exposure for heart specialists and their teams. It could also allow them to wear lighter protective gear-or none at all-making their work safer and more comfortable.\n\nThis study will compare the radiation levels received by doctors and nurses during heart procedures when using RAMPART versus standard protection. By doing so, we hope to find out if this new device can better protect medical teams from radiation, improving both their safety and well-being.",[29,138,139,140],"Radiation Exposure to Operator","Radiation Injuries","Radiation Safety",[142,143,144,145],"radiation exposure","radiation exposure to operator","radiation injuries","radiation safety","2025-11-19",{"date":148,"type":38},"2025-11-24",{"date":150,"type":38},"2025-08-29",{"date":152,"type":21},"2026-03-01",{"name":154,"class":45},"Liverpool Heart and Chest Hospital NHS Foundation Trust",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":162,"targetDuration":164,"studyType":165,"phases":4,"briefSummary":166,"conditions":167,"keywords":173,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":46},"100454877","longitudinal-registry-including-patients-treated-with-heavy-particles-100454877","NCT05203250","Longitudinal Registry Including Patients Treated With Heavy Particles","CNAO REgistry triAL - REGAL","Inclusion Criteria:\n\n* Patients treated with heavy particles at Fondazione CNAO, Pavia\n* Patients who have the ability to understand and be willing to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients or legal guardians who are unable to understand informed consent document",{"count":163,"type":21},3000,"50 Years","OBSERVATIONAL","The purpose of this registry is to collect retrospective and prospective standardized data of patients treated with particle therapy, either with protons or carbon ions, at the National Center for Oncological Hadrontherapy (CNAO) based in Pavia.\n\nBy keeping track of the patients treated, it will allow the investigators to periodically analyze and evaluate data collected of daily clinical activity. This will help gathering more information on the results of particle therapy and will provide the basis for in depth evaluation of patients' outcome with respect to the delivered treatment.",[168,169,29,170,171,172],"Cancer","Oncology","Radiotherapy Side Effect","Radiation Toxicity","Rare Disease",[174,169,168,175,176,177,178,179],"Hadrontherapy","Radiotherapy","Protons","Carbon Ions","Heavy ions","Rare cancer","2025-08-01",{"date":182,"type":38},"2025-08-06",{"date":184,"type":38},"2021-06-04",{"date":186,"type":21},"2071-06-04",{"name":188,"class":45},"CNAO National Center of Oncological Hadrontherapy",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":214},"100593613","phase-3-omitting-ctv-for-primary-tumor-in-ls-sclc-100593613","NCT07008716","Omitting CTV for Primary Tumor in LS-SCLC","Omission of Clinical Target Volume (CTV) for Primary Tumors in Limited-Stage Small Cell Lung Cancer: A Prospective Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Small cell lung cancer confirmed by histology or cytology; TNM stage IA-IIIC (AJCC 8th edition, 2017; limited-stage) without intrapulmonary metastasis;\n2. Aged 18-75 years, KPS score ≥ 80, ≤ 10% weight loss within the past 6 months;\n3. Have measurable lesions per RECIST 1.1 criteria;\n4. Have no disease progression after 2-4 cycles of etoposide\u002Fcarboplatin or etoposide\u002Fcisplatin;\n5. Lung function test: FEV1 ≥ 1 L (Optional);\n6. Complete blood count: neutrophil count ≥ 1.5 x 10\\^9\u002FL, hemoglobin ≥ 100 g\u002FL, platelet count ≥ 100 x 10\\^9\u002FL;\n7. Renal function: serum creatinine ≤ 1.5 x upper limit of normal (ULN);\n8. Liver function: AST and ALT ≤ 2.5 x ULN, bilirubin ≤ 1.5 x ULN;\n9. Fully understand the study, able to complete treatment and follow-up, and voluntarily sign the informed consent.\n\nExclusion Criteria:\n\n1. Other malignant tumors (prior or concurrent), except those that have been curatively treated with disease-free survival ≥ 5 years, such as non-melanoma skin cancer, cervical carcinoma in situ, or early-stage papillary thyroid cancer;\n2. Uncontrolled heart disease or myocardial infarction within the past 6 months;\n3. Patients with a history of mental illness;\n4. Pregnant and lactating patients;\n5. Poorly controlled diabetes and hypertension;\n6. Interstitial pneumonia or active pulmonary fibrosis;\n7. Active infection;\n8. Other conditions unsuitable for enrollment (per investigator judgment).","75 Years",{"count":198,"type":21},852,[200],"PHASE3","This randomized controlled non-inferior trial prospectively enrolled patients with limited-stage small cell lung cancer (LS-SCLC). Patients in the experimental group would receive radiotherapy with omission of the clinical target volume (CTV) for the primary tumor, while those in the control group would receive radiotherapy including CTV. The efficacy and toxicity of the two groups are compared to provide evidence for the radiotherapy of LS-SCLC. The target volume of LS-SCLC may be reduced by omitting CTV without increasing local recurrence but potentially reducing the dose to organs at risk and the side effects.",[203,29,170,204],"SCLC, Limited Stage","Progression","2025-05-29",{"date":207,"type":38},"2025-06-06",{"date":209,"type":21},"2025-06-03",{"date":211,"type":21},"2032-12-31",{"name":213,"class":45},"Sun Yat-sen University",2,{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":223,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":165,"phases":4,"briefSummary":227,"conditions":228,"keywords":231,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":46},"100559949","iops-technology-during-cannnulation-of-contralateral-limb-in-evar-100559949","NCT06570785","IOPS Technology During Cannnulation of Contralateral Limb in EVAR","Contralateral Limb Cannulation Using Intra-Operative Positioning SystemTechnology in Endovascular Aneurysm Repair","IOPS","Inclusion Criteria:\n\n\\- All patients (over 18 years of age) with infrarenal AAA treated between 1st September 2024 and 1st May 2025 undergoing standard EVAR according to the IFU\n\nExclusion Criteria:\n\n* Patients who are pregnant\n* Patients who are under 40 years of age\n* Patients who have symptomatic or ruptured AAA\n* Patients with more advanced AAA: juxtarenal, pararenal, suprarenal, thoracic, thoracoabdominal AAA\n* Non-atherosclerotic origin of disease: dissection, connective tissue disorders, mycotic AAA, posttraumatic AAA\n* Patients who were treated in a conservative manner\n* Patients undergoing open surgery\n* Patients undergoing more advanced treatment options: fenestrated\u002Fbranched EVAR, endostaplers, chimney EVAR, iliac branch devices, etc.","40 Years","100 Years",{"count":226,"type":21},80,"Short-term results are favorable for EndoVascular Aneurysm Repair (EVAR) compared to open surgery. One of the major drawbacks to this shift is the need for fluoroscopy and contrast dyes to visualise endovascular devices. The use of fluoroscopy exposes both patients and caregivers to harmful ionizing radiation. Because of the harmful effects of radiation, recent radiation protection guidelines strongly recommend as low as reasonably achievable (ALARA) principle. The need for additional radiation-reducing navigation techniques is high, with the ultimate goal of performing endovascular procedures without radiation at all.\n\nIn response to these challenges, Centerline Biomedical (Cleveland, Ohio, USA) has developed a proprietary electromagnetic tracking and positioning system called the Intra-Operative Positioning System (IOPS). This medical device provides surgeons with 3D visualization for increased surgical precision while reducing the radiation exposure for patients and healthcare professionals. IOPS provides 3D electromagnetic navigation of interventional devices as an adjunct to fluoroscopy. During the intervention, the IOPS devices can be visualized with on-screen image guidance. The IOPS guidewires and catheters can be used together or combined with off-the-shelf 0.035-inch catheters and guidewires, as needed.\n\nThis study aims to describe the influence of IOPS technology on radiation exposure during cannulation of the contralateral limb (CL) during standard EVAR.",[229,230,29],"Abdominal Aortic Aneurysm","Abdominal Aortic Aneurysm Without Rupture",[229,232,233],"EndoVascular Aneurysm Repair","Radiation Protection","2024-11-17",{"date":236,"type":38},"2024-11-20",{"date":238,"type":21},"2025-01-20",{"date":240,"type":21},"2025-11-03",{"name":242,"class":45},"Clinical Centre of Serbia",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":46},"100543804","ultra-low-dose-ct-and-use-of-iomeron-400-in-pcd-ct-100543804","NCT06360627","Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT","Inclusion Criteria:\n\n* CT SCAN for pulmonary nodule detection\u002Ffollow up\n* CT SCAN for pneumonia detection\u002Ffollow up\n\nExclusion Criteria:\n\n* under 18\n* BMI over 30",{"count":134,"type":21},[24],"Evaluation of ultra low dose protocols and Iomeron 400 contrast in PCD-CT",[29,253,254,255],"Lung Embolism","Lung Cancer","Pneumonia","2024-04-09",{"date":258,"type":38},"2024-04-11",{"date":260,"type":38},"2023-02-20",{"date":262,"type":21},"2027-12-01",{"name":264,"class":45},"University of Zurich",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":22,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":46},"100338458","y90-radioembolization-dose-delivery-and-radiation-exposure-assessment-100338458","NCT03686709","Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment","Inclusion Criteria:\n\n* All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study\n* Must be able to schedule and tolerate additional PET\u002FCT imaging following therapy\n* Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure.\n\nExclusion Criteria:\n\n* Patients that are not candidates for Y90 radioembolization therapy\n* Patients that cannot tolerate additional imaging procedures following therapy\n* Patients that cannot tolerate the additional blood draws required for this study\n* Patients whose schedule does not allow them to remain at the hospital for the additional PET\u002FCT imaging study",{"count":272,"type":21},20,[24],"The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.",[276,29],"Hepatocellular Carcinoma","2018-09-25",{"date":279,"type":38},"2018-09-27",{"date":281,"type":38},"2018-06-19",{"date":283,"type":21},"2019-12-31",{"name":285,"class":45},"University of Tennessee"]